China Bribery Scandal Could Provide Fodder For U.S. Foreign Corrupt Practices Act Investigations
This article was originally published in The Pink Sheet Daily
Companies under scrutiny in China for allegedly bribing doctors could face new enforcement actions in the U.S. Lilly’s ability to avoid another FCPA investigation may depend on whether the SEC was aware of whistleblower allegations made in the Chinese press.
You may also be interested in...
High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.
As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.
COVID-19 Therapeutic Trials: Investigators Should Join Forces Rather Than Conduct Single Site Studies
‘Treacherous combination’ of small clinical trials, lagging enrollment, unreported results and uncompleted trials is hindering COVID-19 research, former FDA Commissioner Califf says. Yale professor calls for a ‘Manhattan Project’ around knowledge and a change in the academic star system.